Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 368卷
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Opioid overdose deaths and the expansion of opioid agonist treatment: a population-based prospective cohort study
    Rogeberg, Ole
    Bergsvik, Daniel
    Clausen, Thomas
    ADDICTION, 2022, 117 (05) : 1363 - 1371
  • [2] Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records br
    Domzaridou, Eleni
    Carr, Matthew J.
    Webb, Roger T.
    Millar, Tim
    Ashcroft, Darren M.
    LANCET REGIONAL HEALTH-EUROPE, 2022, 22
  • [3] Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study
    Paul, Lauren A.
    Bayoumi, Ahmed M.
    Chen, Cynthia
    Kocovska, Elena
    Smith, Brendan T.
    Raboud, Janet M.
    Gomes, Tara
    Kendall, Claire
    Rosella, Laura C.
    Bitonti-Bengert, Lisa
    Rush, Brian
    Yu, Melissa
    Spithoff, Sheryl
    Crichlow, Frank
    Wright, Amy
    Watford, Jase
    Besharah, Jes
    Munro, Charlotte
    Taha, Sheena
    Nosyk, Bohdan
    Strike, Carol
    Manson, Heather
    Kahan, Meldon
    Leece, Pamela
    ADDICTION, 2023, 118 (04) : 686 - 697
  • [4] Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study
    Tipping, Andrew D.
    Nowels, Molly
    Moore, Clara
    Samples, Hillary
    Crystal, Stephen
    Olfson, Mark
    Williams, Arthur Robinson
    -Woodruff, Jodi Heaps
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 157
  • [5] Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality A Cohort Study
    Larochelle, Marc R.
    Bernson, Dana
    Land, Thomas
    Stopka, Thomas J.
    Wang, Na
    Xuan, Ziming
    Bagley, Sarah M.
    Liebschutz, Jane M.
    Walley, Alexander Y.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (03) : 137 - +
  • [6] Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
    Macmadu, Alexandria
    Paull, Kimberly
    Youssef, Rouba
    Batthala, Sivakumar
    Wilson, Kevin H.
    Samuels, Elizabeth A.
    Yedinak, Jesse L.
    Marshall, Brandon D. L.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 226
  • [7] Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
    Macmadu, Alexandria
    Paull, Kimberly
    Youssef, Rouba
    Batthala, Sivakumar
    Wilson, Kevin H.
    Samuels, Elizabeth A.
    Yedinak, Jesse L.
    Marshall, Brandon D. L.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 219
  • [8] The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study
    Bharat, Chrianna
    Larney, Sarah
    Barbieri, Sebastiano
    Dobbins, Timothy
    Jones, Nicola R.
    Hickman, Matthew
    Gisev, Natasa
    Ali, Robert
    Degenhardt, Louisa
    ADDICTION, 2021, 116 (11) : 3139 - 3152
  • [9] Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services
    Krawczyk, Noa
    Mojtabai, Ramin
    Stuart, Elizabeth A.
    Fingerhood, Michael
    Agus, Deborah
    Lyons, B. Casey
    Weiner, Jonathan P.
    Saloner, Brendan
    ADDICTION, 2020, 115 (09) : 1683 - 1694
  • [10] Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study
    Kimber, Jo
    Larney, Sarah
    Hickman, Matthew
    Randall, Deborah
    Degenhardt, Louisa
    LANCET PSYCHIATRY, 2015, 2 (10): : 901 - 908